Gapping up
In reaction to strong earnings/guidance: PFIE +3.1%.
M&A news: TSPT +25.6% (co and Paratek Pharmaceuticals sign merger agreement), COO +3.3% (announces definitive agreements to acquire Sauflon Pharmaceuticals), .
Select EU financial related names showing strength: NBG +1.4%, ING +1.4%, UBS +1.3%, BCS +1.2%.
Select metals/mining stocks trading higher: RIO +1.2%, GOLD +0.8%, BHP +0.6%.
Other news: PVCT +26.7% (still checking), AGEN +22.7% (vaccine shows extended survival in phase 2 final data analysis), GALE +11.8% (announces notice of allowance of broad U.S. Patent for NeuVax), SLXP +11.1% (announces statistically significant primary endpoint result for TARGET 3 evaluating the efficacy and safety of repeat treatment with Rifaximin 550mg), GPRO +8.7% (positive mention on Mad Money), OGXI +7.2% (announces Cedar clinical trial evaluating apatorsen in combination with chemotherapy in advanced squamous cell lung cancer is now open for enrollment), EVRY +6.2% (provides update on credit agreements), MY +6.1% (strong Chinese PMI data overnight), CTIC +5.3% (completes recruitment in PERSIST-1 pivotal Phase 3 trial of Pacritinib for patients with myelofibrosis; expects to receive $20 mln development milestone payment from Baxter (BAX)), FEYE +2.1% (positive mention on Mad Money), BK +1.9% (positive mention on Mad Money), GMCR +1.1% (announced a multiyear agreement to bring Nestle (NSRGY) to bring Coffee-Mate branded coffee to K-Cup packs for the Keurig brewing system), MPEL +1% (positive Macau data).
Analyst comments: FOLD +9.9% (upgraded to Buy from Neutral at Janney, upgraded to Outperform from Mkt Perform at Leerink Partners), NFLX +4% (upgraded to Buy from Neutral at Goldman), ANET +3.9% (initiated with a Outperform at RBC Capital Mkts, initiated with a Buy at Deutsche Bank, among others), ICPT +3.1% (initiated with Outperform and $425 tgt at RBC Capital Markets),JD +2.7% (initiated with a Overweight at Barclays, and several other intiations), NBR +2.1% (upgraded to Outperform from Mkt Perform at Raymond James), HCLP +1.3% (target raised to $65 at Wunderlich), HIMX +1.3% (positive comments at Northland), CPTA +1.1% (initiated with a Buy at Wunderlich), PCLN +0.8% (initiated with Outperform and $1450 tgt at Oppenheimer)
In reaction to strong earnings/guidance: PFIE +3.1%.
M&A news: TSPT +25.6% (co and Paratek Pharmaceuticals sign merger agreement), COO +3.3% (announces definitive agreements to acquire Sauflon Pharmaceuticals), .
Select EU financial related names showing strength: NBG +1.4%, ING +1.4%, UBS +1.3%, BCS +1.2%.
Select metals/mining stocks trading higher: RIO +1.2%, GOLD +0.8%, BHP +0.6%.
Other news: PVCT +26.7% (still checking), AGEN +22.7% (vaccine shows extended survival in phase 2 final data analysis), GALE +11.8% (announces notice of allowance of broad U.S. Patent for NeuVax), SLXP +11.1% (announces statistically significant primary endpoint result for TARGET 3 evaluating the efficacy and safety of repeat treatment with Rifaximin 550mg), GPRO +8.7% (positive mention on Mad Money), OGXI +7.2% (announces Cedar clinical trial evaluating apatorsen in combination with chemotherapy in advanced squamous cell lung cancer is now open for enrollment), EVRY +6.2% (provides update on credit agreements), MY +6.1% (strong Chinese PMI data overnight), CTIC +5.3% (completes recruitment in PERSIST-1 pivotal Phase 3 trial of Pacritinib for patients with myelofibrosis; expects to receive $20 mln development milestone payment from Baxter (BAX)), FEYE +2.1% (positive mention on Mad Money), BK +1.9% (positive mention on Mad Money), GMCR +1.1% (announced a multiyear agreement to bring Nestle (NSRGY) to bring Coffee-Mate branded coffee to K-Cup packs for the Keurig brewing system), MPEL +1% (positive Macau data).
Analyst comments: FOLD +9.9% (upgraded to Buy from Neutral at Janney, upgraded to Outperform from Mkt Perform at Leerink Partners), NFLX +4% (upgraded to Buy from Neutral at Goldman), ANET +3.9% (initiated with a Outperform at RBC Capital Mkts, initiated with a Buy at Deutsche Bank, among others), ICPT +3.1% (initiated with Outperform and $425 tgt at RBC Capital Markets),JD +2.7% (initiated with a Overweight at Barclays, and several other intiations), NBR +2.1% (upgraded to Outperform from Mkt Perform at Raymond James), HCLP +1.3% (target raised to $65 at Wunderlich), HIMX +1.3% (positive comments at Northland), CPTA +1.1% (initiated with a Buy at Wunderlich), PCLN +0.8% (initiated with Outperform and $1450 tgt at Oppenheimer)